Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus.
Fiche du document
2014
- doi: 10.4414/smw.2014.13913
- issn: 0036-7672
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.4414/smw.2014.13913
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/24652665
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1424-3997
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B279E13B1B710
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Blood pressure, High Vascular hypertension High blood pressureCiter ce document
G. Wuerzner et al., « Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus. », Serveur académique Lausannois, ID : 10.4414/smw.2014.13913
Métriques
Partage / Export
Résumé
Transcatheter (or percutaneous) renal denervation is a novel technique developed for the treatment of resistant hypertension. So far, only one randomised controlled trial has been published, which has shown a reduction of office blood pressure. The Swiss Society of Hypertension, the Swiss Society of Cardiology, The Swiss Society of Angiology and the Swiss Society of Interventional Radiology decided to establish recommendations to practicing physicians and specialists for good clinical practice. The eligibility of patients for transcatheter renal denervation needs (1.) confirmation of truly resistant hypertension, (2.) exclusion of secondary forms of hypertension, (3.) a multidisciplinary decision confirming the eligibility, (4.) facilities that guarantee procedural safety and (5.) a long-term follow-up of the patients, if possible in cooperation with a hypertension specialist. These steps are essential until long-term data on safety and efficacy are available.